基于肠促胰岛素的代谢功能障碍相关脂肪性肝病治疗进展:从单受体到双受体或三受体激动剂
代谢功能障碍相关脂肪性肝病(MASLD)及代谢功能障碍相关脂肪性肝炎(MASH)缺乏有效药物治疗。GLP-1受体激动剂已在2期随机临床试验中显示组织学改善并推进至3期;GIP和/或胰高血糖素受体激动剂等新型单、双、三受体激动剂在2期试验中显示对MASLD/MASH组织学及肝外并发症的益处。本叙述性综述总结肠促胰岛素类药物治疗MASLD/MASH的临床证据及潜在肝保护机制。
要点
- GLP-1受体激动剂在MASLD/MASH的2期随机临床试验中取得成功,已推进至3期临床试验,主要测试皮下司美格鲁肽的长期疗效。
- GIP和/或胰高血糖素受体激动剂等新型单、双或三受体激动剂在2期随机临床试验中显示MASLD/MASH组织学改善及肝外并发症获益。
- 单、双或三肠促胰岛素受体激动剂正成为MASLD或MASH有吸引力的治疗选择,尤其适用于合并肥胖或2型糖尿病的个体。
核心结论
- 单、双或三肠促胰岛素受体激动剂正成为MASLD或MASH有吸引力且有前景的治疗选择,尤其适用于合并肥胖或2型糖尿病的个体。
研究设计与样本
- 叙述性综述,检索并汇总肠促胰岛素类药物治疗MASLD/MASH的临床证据及肠促胰岛素生物学与肝保护机制。
主要发现
- GLP-1受体激动剂在MASLD/MASH的2期随机临床试验中取得成功,已推进至3期临床试验,主要测试皮下司美格鲁肽的长期疗效。
- GIP和/或胰高血糖素受体激动剂等新型药物在2期随机临床试验中显示MASLD/MASH组织学改善及MASLD相关肝外并发症获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinically effective pharmacological treatment(s) for metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) represent a largely unmet need in medicine. Since glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been licensed for the treatment of type 2 diabetes mellitus and obesity, they were one of the first drug classes to be examined in individuals with MASLD/MASH. Successful phase 2 randomised clinical trials with these agents have resulted in progression to phase 3 clinical trials (principally testing the long-term efficacy of subcutaneous semaglutide). Over the last few years, in addition to GLP-1RAs, newer agents with glucose-dependent insulinotropic peptide and/or glucagon receptor agonist functions have been tested, with increasing evidence from phase 2 randomised clinical trials of histological improvements in MASLD/MASH, as well as benefits on MASLD-related extrahepatic complications. Based on this background of evidence, single, dual or triple incretin receptor agonists are becoming an attractive and promising treatment option for MASLD or MASH, particularly in individuals with coexisting obesity or type 2 diabetes mellitus. In this narrative review, we examine the rapidly expanding body of clinical evidence supporting a role of incretin-based pharmacotherapies in delaying or reversing MASH progression. We also discuss the biology of incretins and the putative hepatoprotective mechanisms of incretin-based pharmacotherapies for managing MASLD or MASH.
引用
- Targher G, Mantovani A, Byrne CD, et al. Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists. Gut. 2025. PMID: 39592207. doi:10.1136/gutjnl-2024-334023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。